Back to Journals » Journal of Multidisciplinary Healthcare » Targeting Non-Alcoholic Fatty Liver Disease: Lifestyle, Pharmacotherapy, and Beyond
Journal of Multidisciplinary Healthcare
- View all (3205)
- Volume 19, 2026 (269)
- Volume 18, 2025 (620)
- Volume 17, 2024 (536)
- Volume 16, 2023 (392)
- Volume 15, 2022 (249)
- Volume 14, 2021 (335)
- Volume 13, 2020 (205)
- Volume 12, 2019 (106)
- Volume 11, 2018 (71)
- Volume 10, 2017 (48)
- Volume 9, 2016 (70)
- Volume 8, 2015 (58)
- Volume 7, 2014 (63)
- Volume 6, 2013 (47)
- Volume 5, 2012 (39)
- Volume 4, 2011 (49)
- Volume 3, 2010 (23)
- Volume 2, 2009 (8)
- Volume 1, 2008 (16)
Journal Articles:
- Building a Sustainable Allied Health Workforce: Recruitment, Retention, and Resilience (2)
- A Multidisciplinary Approach to Reducing Suicide Risk Among Adolescents: Strategies, Challenges, and Solutions (4)
- Global Advances in Pharmacogenomics: From Discovery to Clinical Implementation and Improved Patient Outcomes (1)
- Allied Health Matters: Showcasing Value, Driving Impact (7)
- Strengthening Multidisciplinary Healthcare Teams: Workforce Integration, Team Collaboration, and Equitable Care (1)
- Harnessing Database Mining for Advancing Clinical Practice: From Insights to Therapeutic Innovation (10)
- Cybersecurity in Healthcare: Ensuring Patient Safety and Data Privacy (2)
- Children with Disabilities and Chronic Diseases: Perspectives, Challenges, and Opportunities (6)
- Exploring the Intersection of Internet Addiction and Pain Syndromes (1)
- Advancing Pharmacogenetics in Limited Resources Countries: Affordable Testing Methods, Genetic Variability, and Clinical Implications (1)
- Unraveling AI: The Use of Interactive AI, Conversational AI, and Generative AI in Teaching and Learning or Health and Care (1)
- Crosstalk in multidisciplinary approaches for evidence-based medicine (6)
Targeting Non-Alcoholic Fatty Liver Disease: Lifestyle, Pharmacotherapy, and Beyond
Non-alcoholic fatty liver disease (NAFLD) has rapidly become one of the most significant liver disorders globally, affecting nearly a quarter of the world’s population. It encompasses a spectrum of liver conditions, starting with simple steatosis (fat accumulation in hepatocytes) and progressing in some individuals to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). This Article Collection aims to explore the latest advancements in NAFLD management, from foundational lifestyle interventions to cutting-edge pharmacological and non-pharmacological strategies.